Reference list Board members

2022 – Reference list of hepatitis publications of the VHPB board members

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Polaris Observatory HCV Collaborators. Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. doi: 10.1016/S2468-1253(21)00472-6. Epub 2022 Feb 16.PMID: 35180382 Review.

Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach. Busschots D, Ho E, Blach S, Nevens F, Razavi H, Van Damme B, Vanwolleghem T, Robaeys G. BMC Infect Dis. 2022 Apr 22;22(1):397. doi: 10.1186/s12879-022-07378-3.PMID: 35459120

The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia. Gamkrelidze A, Handanagic S, Shadaker S, Turdziladze A, Tsereteli M, Getia V, Aslanikashvili A, Surguladze S, Gvinjilia L, Kuchuloria T, Tskhomelidze I, Armstrong PA. Public Health. 2022 Apr;205:182-186. doi: 10.1016/j.puhe.2022.01.040. Epub 2022 Feb 9. PMID: 35305459; PMCID: PMC9004234.

Door-to-door hepatitis C screening in Georgia: An innovative model to increase testing and linkage to care. Butsashvili M, Zurashvili T, Kamkamidze G, Kajaia M, Gulbiani L, Gamezardashvili A, Gvinjilia L, Kuchuloria T, Gamkrelidze A, Shadaker S, Nasrullah M, Averhoff F, Armstrong PA. J Med Screen. 2022 Mar 16:9691413221086497. doi: 10.1177/09691413221086497. Epub ahead of print. PMID: 35293802.

Hepatitis B Prevalence and Risk Factors in Punjab, India: A Population-Based Serosurvey. Shaun Shadaker, Ajit Sood, Francisco Averhoff, Anil Suryaprasad, Subodh Kanchi, Vandana Midha, Saleem Kamili, Muazzam Nasrullah, Adam Trickey, Ravinder Garg, Pramod Mittal, Suresh K. Sharma, Peter Vickerman, Paige A. Armstrong. Journal of Clinical and Experimental Hepatology, 2022, https://doi.org/10.1016/j.jceh.2022.04.014.

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Polaris Observatory HCV Collaborators. The Lancet Gastroenterology & Hepatology 2022.

HCV disease burden and population segments in Switzerland. Bihl F, Bruggmann P, Castro Batänjer E, Dufour J-F, Lavanchy D, Müllhaupt B, Negro F, Razavi H, Scheidegger C, Semela D, Semmo N, Blach S. Liver International 2022;42:330-339.

 

2021 – Reference list of hepatitis publications of the VHPB board members

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial. Vesikari T, Finn A, Van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N, Toma A, Vallieres G, Aronson R, Reich D, Arora S, Ruane PJ, Cone CL, Manns M, Cosgrove C, Faust SN, Ramasamy MN, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson D, Popovic V, Diaz-Mitoma F; CONSTANT Study Group. JAMA Netw Open. 2021 Oct 1;4(10):e2128652.

A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region. Badur S, Öztürk S, Ozakay A, Khalaf M, Saha D, Van Damme PHum Vaccin Immunother. 2021 Oct 3;17(10):3710-3728. doi: 10.1080/21645515.2021.1920871. 

Sexual Dimorphism in Hepatocyte Xenograft Models. Sari G, van Oord GW, van de Garde MDB, Voermans JJC, Boonstra A, Vanwolleghem TCell Transplant. 2021 Jan-Dec;30:9636897211006132. doi: 10.1177/09636897211006132.33938243

Treatment induced clearance of hepatitis E viruses by interferon-lambda in liver-humanized mice. Sari G, Mulders CE, Zhu J, van Oord GW, Feng Z, Kreeft-Voermans JJC, Boonstra A, Vanwolleghem T. Liver Int. 2021 Dec;41(12):2866-2873. doi: 10.1111/liv.15033. Epub 2021 Aug 29.PMID: 34392598

Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Gastroenterology. 2022 Mar;162(3):757-771.e4. doi: 10.1053/j.gastro.2021.11.002. Epub 2021 Nov 9.PMID: 34762906

Clinical management of chronic hepatitis B: A concise overview. Furquim d’Almeida A, Ho E, Van Hees S, Vanwolleghem T. United European Gastroenterol J. 2022 Feb;10(1):115-123. doi: 10.1002/ueg2.12176. Epub 2021 Nov 30.PMID: 34846093. Review.

Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV. Vanwolleghem T, Adomati T, Van Hees S, Janssen HLA. JHEP Rep. 2021 Nov 19;4(2):100398. doi: 10.1016/j.jhepr.2021.100398. eCollection 2022 Feb.PMID: 35059620. Review.

Hepatitis A outbreak characteristics: a comparison of regions with different vaccination strategies, Spain 2010–2018. Domínguez A, Varela C, Soldevila N, Izquierdo C, Guerrero M, Peñuelas M, Martínez A, Godoy P, Borràs E, Rius C, Torner N, Avellón AM, Castilla J, and PREVICET Working Group on Viral Hepatitis. Vaccines (Basel). 2021 Oct 20;9(11):1214. doi: 10.3390/vaccines9111214.

The Viral ORF3 Protein Is Required for Hepatitis E Virus Apical Release and Efficient Growth in Polarized Hepatocytes and Humanized Mice. Sari G, Zhu J, Ambardekar C, Yin X, Boonstra A, Feng Z, Vanwolleghem T. J Virol. 2021 Nov 9;95(23):e0058521. doi: 10.1128/JVI.00585-21. Epub 2021 Sep 15.PMID: 34523963

Thalassemia Patients from Baluchistan in Pakistan Are Infected with Multiple Hepatitis B or C Virus Strains. Ahmed S, Ayub M, Naeem M, Nazir FH, Hussain A, Ghilzai D, Magnius LO, Sajjad A, Norder H. Am J Trop Med Hyg. 2021 Feb 1;104(4):1569–76. doi: 10.4269/ajtmh.20-0740. Epub ahead of print. PMID: 33534738; PMCID: PMC8045631.

The case for simplifying and using absolute targets for viral hepatitis elimination goals. J Viral Hepat 2021;28(1):12-19. The Polaris Collaborators. Doi: 10.1111/jvh.13412.

Recommandations pour le suivi des patients atteints d’hépatite C guérie – Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. Bobzin C, Bösiger C, Bruggmann P, Cerny A, Fraga Christinet M, Keiser O, Künzler-Heulec P, Lavanchy D, Maeschli B, Moradpour D, Negro F, Rauch A, Scheidegger C, Semela D, Semmo N, Thurnheer MC. Swiss Med Forum 2021;21:184-186.

The case for simplifying and using absolute targets for viral hepatitis elimination goals. Polaris Observatory Collaborators. J Viral Hepat. 2021 Jan;28(1):12-19. doi: 10.1111/jvh.13412. Epub 2020 Nov 4.PMID: 3297988

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. J Hepatol. 2021 ;74(4):944-951.

Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Cell Immunol. 2021 Apr;362:104283. doi: 10.1016/j.cellimm.2021.104283. Epub 2021 Jan 9.Cell Immunol. 2021. PMID: 33548734

Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study.

Bourgeois S, Mulkay JP, Cool M, Verhelst X, Robaeys G, Lasser L, Lefebvre V, Colle I, Van Steenkiste C, Decaestecker J, Coulon S, Venken K, Vanwolleghem T. Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):33-41.Acta Gastroenterol Belg. 2021. PMID: 33639691 Free article.

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. Markus Cornberg, Maria Buti, Christiane S Eberhardt, Paolo Antonio Grossi, Daniel Shouval. J Hepatol. 2021 Apr;74(4):944-951.

Performance of rapid diagnostic tests for hepatitis B surface antigen detection in serum or plasma.

Chevaliez S, Roudot-Thoraval F, Hézode C, Pawlotsky JM, Njouom R. Diagn Microbiol Infect Dis. 2021 Feb 17;100(2):115353. doi: 10.1016/j.diagmicrobio.2021.115353. Online ahead of print.

Epidemiology of hepatitis C virus infection. Roudot-Thoraval F. Clin Res Hepatol Gastroenterol. 2021 Feb 17;45(3):101596. doi: 10.1016/j.clinre.2020.101596. Online ahead of print.

2020 – Reference list of hepatitis publications of the VHPB board members

Hepatitis E virus genotype 3 strains and a plethora of other viruses detected in raw and still in tap water. Wang H, Kjellberg I, Sikora P, Rydberg H, Lindh M, Bergstedt O, Norder H. Water Res. 2020 Jan 1;168:115141. doi: 10.1016/j.watres.2019.115141. Epub 2019 Sep 30. PMID: 31590036.

Launch of the Coalition for Global Hepatitis Elimination: a recommendation of the Lancet Gastroenterology & Hepatology Commission. Ward JW, Wiktor SZ, Cooke GS. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):8-10. doi: 10.1016/S2468-1253(19)30319-X.

Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Posuwan N, Wanlapakorn N, Vongpunsawad S, Sintusek P, Leuridan E, Van Damme P, Poovorawan Y. Vaccine. 2020 Feb 11;38(7):1643-1651. doi: 10.1016/j.vaccine.2019.12.065. Epub 2020 Jan 14. PMID: 31948817.

Securing sustainable funding for viral hepatitis elimination plans. Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP. Liver Int. 2020 Feb;40(2):260-270. DOI: 10.1111/liv.14282

Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials. Poordad F, Castro RE, Asatryan A, Aguilar H, Cacoub P, Dieterich D, Marinho RT, Carvalho A, Siddique A, Hu YB, Charafeddine M, Bondin M, Khan N, Cohen DE, Felizarta F. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261.

Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. Vanwolleghem T, Groothuismink ZMA, Kreefft K, Hung M, Novikov N, Boonstra A. J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30071-4. doi: 10.1016/j.jhep.2020.01.024.

Hepatitis B Virus RNA Profiles in Liver Biopsies by Digital Polymerase Chain Reaction. Prakash K, Larsson SB, Rydell GE, Andersson ME, Ringlander J, Norkrans G, Norder H, Lindh M. Hepatol Commun. 2020 Mar 29;4(7):973-982. doi: 10.1002/hep4.1507. PMID: 32626830; PMCID: PMC7327224.

Nivolumab and anti-HCV activity, a case report. Wuyts L, Janssens A, Vonghia L, Michielsen P, Raskin J, Driessen A, Van Hees S, Francque S, Vanwolleghem T. Acta Clin Belg. 2020 Mar 17:1-5. doi: 10.1080/17843286.2020.1741897.

A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy. Dams K, Burger DM, Weyler J, Francque S, Jorens PG, Vanwolleghem T. Clin Biochem. 2020 Sep;83:86-88. doi: 10.1016/j.clinbiochem.2020.05.015. Epub 2020 May 30. PMID: 32485171

ICTV Virus Taxonomy Profile: <i>Hepadnaviridae</i>. Magnius L, Mason WS, Taylor J, Kann M, Glebe D, Dény P, Sureau C, Norder H, Ictv Report Consortium. J Gen Virol. 2020 Jun;101(6):571-572. doi: 10.1099/jgv.0.001415. PMID: 32416744; PMCID: PMC7414443.

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. JHEP Rep. 2020 Jun;2(3):100113. DOI: 10.1016/j.jhebpr.2020.100113

Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs. Chevaliez S, Wlassow M, Volant J, Roudot-Thoraval F, Bachelard A, Poiteau L, Trabut JB, Hézode C, Bourdel A, Dominguez S. Open Forum Infect Dis. 2020 May 26;7(6):ofaa196. doi: 10.1093/ofid/ofaa196. eCollection 2020 Jun.PMID: 32617372

Hepatitis E virus is an infrequent but potentially serious infection in allogeneic hematopoietic stem cell transplant recipients. Swartling L, Nordén R, Samuelsson E, Boriskina K, Valentini D, Westin J, Norder H, Sparrelid E, Ljungman P. Bone Marrow Transplant. 2020 Jul;55(7):1255-1263. doi: 10.1038/s41409-020-0823-7. Epub 2020 Feb 18. PMID: 32071417.

Update: proposed reference sequences for subtypes of hepatitis E virus (species <i>Orthohepevirus A</i>). Smith DB, Izopet J, Nicot F, Simmonds P, Jameel S, Meng XJ, Norder H, Okamoto H, van der Poel WHM, Reuter G, Purdy MA. J Gen Virol. 2020 Jul;101(7):692-698. doi: 10.1099/jgv.0.001435. PMID: 32469300; PMCID: PMC7660235.

Hepatology in the COVID era: another C virus, again challenging in the liver. Peixe P, Calinas F, Marinho RT. GE Port J Gastroenterol. 2020 Jul;27(4):230-236. doi: 10.1159/000508116.

Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care

and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in

an Asian Migrant Population. Ho E, Michielsen P, Van Damme P, Ieven M, Veldhuijzen I, Vanwolleghem T. Ann Glob Health. 2020 Jul 16;86(1):81. doi: 10.5334/aogh.2848. PMID: 32742939; PMCID: PMC7366862.

Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. Ho E, Michielsen P, Van Damme P, Ieven M, Veldhuijzen I, Vanwolleghem T. Ann Glob Health. 2020 Jul 16;86(1):81. doi: 10.5334/aogh.2848. PMID: 32742939

Elimination of hepatitis C in Europe: can WHO targets be achieved? Maticic M, Lombardi A, Mondelli MU, Colombo M, ESCMID Study Group for Viral Hepatitis (ESGVH). Clin Microbiol Infect. 2020 Jul;26(7): 818-823. DOI: 10.1016/j.cmi.2020.01.014

Elimination of viral hepatitis: where do we stand in the year 2020? Maticic M, Mondelli MU. Clin Microbiol Infect 2020 Jul;26(7):816-817. DOI: 10.1016/j.cmi.2020.02.029

Early detection of chronic hepatitis B and risk factor assessment in Turkish

migrants, Middle Limburg, Belgium. Koc ÖM, Kremer C, Hens N, Bielen R, Busschots D, Van Damme P, Robaeys G. PLoS One. 2020 Jul 27;15(7):e0234740. doi: 10.1371/journal.pone.0234740. PMID: 32716949; PMCID: PMC7384618.

The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. Palayew A, Stumo SR, Cooke GS, Hutchinson SJ, Jauffret-Roustide M, Maticic M, Harris M, Metwally AM, Razavi H, Lazarus JV, Hep-CORE Study Group. PLoS One. 2020 Jul 28;15(7):e0235715. DOI: 10.1371/journal.pone.0235715.

Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, Scholtes C, Roche B, Castelnau C, Poynard T, Chazouillères O, Ganne N, Fontaine H, Gournay J, Guyader D, Le Gal F, Nahon P, Roudot-Thoraval F, Gordien E; Deltavir study group. J Hepatol. 2020 Nov;73(5):1046-1062. doi: 10.1016/j.jhep.2020.06.038. Epub 2020 Jul 4.PMID: 32634548 

Prevalence of hepatitis C in the adult population of Bulgaria: a pilot study. Sperle I, Nielsen S, Gassowski M, Naneva Z, Perchemlieva T, Amato-Gauci A, An der Heiden M, Bremer V, Golkocheva-Markova E, Hristov K, Kaneva E, Simeonova Y, Tenev T, Varleva T, Duffell E, Zimmermann R. BMC Res Notes. 2020 Jul 7;13(1):326.

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, Streinu-Cercel A, Bourgeois S, Buti M, Crespo J, Manuel Pascasio J, Sarrazin C, Vanwolleghem T, Shukla U, Fry J, Yogaratnam JZ. Gastroenterology. 2020 Aug;159(2):521-533.e9. doi: 10.1053/j.gastro.2020.04.036. Epub 2020 Apr 25. PMID: 32343960

Hospital discharges of hepatocellular carcinoma and non-alcohol related cirrhosis in the EU/EEA and United Kingdom: a descriptive analysis of 2004-2015 data. Nakitanda AO, Duffell E. Infect Dis (Lond). 2020 Nov;52(11):816-827. doi: 10.1080/23744235.2020.1799068. Epub 2020 Aug 25.

Abundance of non-circular intrahepatic hepatitis B virus DNA may reflect frequent integration into human DNA in chronically infected patients. Rydell GE, Larsson SB, Prakash K, Andersson M, Norder H, Hellstrand K, Norkrans G, Lindh M. J Infect Dis. 2020 Sep 10:jiaa572. doi: 10.1093/infdis/jiaa572. Epub ahead of print. PMID: 32910825.

Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Zarski JP, David-Tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret MN, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-Thoraval F, Nahon P. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):524-531. doi: 10.1016/j.clinre.2019.11.005. Epub 2019 Dec 12.

The case for simplifying and using absolute targets for viral hepatitis elimination goals. Homie Razavi, Sarah Blach, Devin Razavi-Shearer, Polaris Observatory Collaborators. J Viral Hepat 2020 Sep 26.  doi: 10.1111/jvh.13412.

Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline. Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Infect Dis (Lond). 2020 Sep;52(9):625-637.

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. JHEP Rep. 2020 Oct; 2(5): 100169. DOI: 10.1016/j.jhepr.2020.100169

The History of Hepatitis A. Shouval D. Clin Liver Dis (Hoboken). 2020 Oct 7;16(Suppl 1):12-23.

A new assay for quantitative detection of hepatitis A virus. Persson S, Alm E, Karlsson M, Enkirch T, Norder H, Eriksson R, Simonsson M, Ellström P. J Virol Methods. 2021 Feb;288:114010. doi: 10.1016/j.jviromet.2020.114010. Epub 2020 Nov 2. PMID: 33152410.

Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. Mulder MB, de Man RA, Kamar N, Durmaz G, de Bruijne J, Vanwolleghem T, Izopet J, Gandia P, van der Eijk AA, van Gelder T, Hesselink DA, de Winter BCM. J Viral Hepat. 2020 Nov 1. doi: 10.1111/jvh.13432. Online ahead of print. PMID: 33135238

Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa – the case of Uganda. Van Hees S, Muyindike W, Erem G, Ocama P, Seremba E, Paska A, Michielsen P, Okwir M, Vanwolleghem T. J Hepatol. 2020 Nov;73(5):1271-1273. doi: 10.1016/j.jhep.2020.05.045. Epub 2020 Aug 14. PMID: 32800587

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, Duffell E, Tammi T, Schatz E. Harm Reduct J. 2020 Nov 19;17(1):89.

Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. BMC Public Health. 2020 Nov 9;20(1):1670.

EASL Policy statement: Drug use and the global hepatitis C elimination goal. Maticic M, Buti M, Craxi A, Leite RB, Negro F, Berg T.  European Association for the Study of the Liver, Geneva: August 2020.

Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA. Ringlander J, Skoglund C, Prakash K, Andersson ME, Larsson SB, Tang KW, Rydell GE, Abrahamsson S, Castedal M, Norder H, Hellstrand K, Lindh M. J Viral Hepat. 2020 Nov;27(11):1162-1170. doi: 10.1111/jvh.13356. Epub 2020 Jul 16. PMID: 32592629.

Stable HEV IgG seroprevalence in Belgium between 2006 and 2014. Ho E, Schenk J, Hutse V, Suin V, Litzroth A, Blaizot S, Herzog SA, Verburgh V, Jacques M, Rahman A, Michielsen P, Van Damme P, Van Gucht S, Theeten H, Hens N, Vanwolleghem T. J Viral Hepat. 2020 Nov;27(11):1253-1260. doi: 10.1111/jvh.13347. Epub 2020 Jul 12. PMID: 32564516.

Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. BMC Public Health. 2020 Nov 9;20(1):1670. doi: 10.1186/s12889-020-09515-6.

Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020. Simões D, Stengaard AR, Combs L, Raben D, EuroTEST COVID-19 impact assessment consortium of partners. Euro Surveill. 2020 Nov;25(47):2001943. doi: 10.2807/1560-7917.ES.2020.25.47.2001943.

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, Duffel E, Tammi T, Schatz E. Harm Reduct J. 2020; 17:89 (nov 19). DOI: 10.1186/s12954-020-00439-3

Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. Mulder MB, de Man RA, Kamar N, Durmaz G, de Bruijne J, Vanwolleghem T, Izopet J, Gandia P, van der Eijk AA, van Gelder T, Hesselink DA, de Winter BCM. J Viral Hepat. 2021 Feb;28(2):431-435. doi: 10.1111/jvh.13432. Epub 2020 Nov 15.J Viral Hepat. 2021. PMID: 33135238 Free PMC article.

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.

Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Séror O, Larrey E, Lim C, Scatton O, El Mouhadi S, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Dioguardi Burgio M, Vilgrain V, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Roudot-Thoraval F, Bouattour M, Nault JC; Paris Liver Cancer Group. JHEP Rep. 2021 Feb;3(1):100199. doi: 10.1016/j.jhepr.2020.100199. Epub 2020 Dec 22.PMID: 33163949

A centralised novel coronavirus telephone helpline: a tool for managing and tracking the nation’s response to the COVID-19 epidemic in Slovenia. Pelicon K, Krajnc I, Petek K, Maticic M. Zdrav Vestn 2020: 89: 702-709. https://doi.org/10.6016/ZdravVestn.3126

Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. Rodríguez-Tajes S, Domínguez A, Carrión JA, Buti M, Quer JC, Morillas RM, López C, Torras X, Baliellas C, Vergara M, Forner M, Zaragoza N, Salò J, Rigau J, Caballeria Ll, Mariño Z, Jané M, Colom J, Forns X, Lens S. Journal of Gastroenterology and Hepatology 2020; in press

Can hepatitis A outbreaks in men who have sex with men be controlled? Domínguez A, Forns X. Revista Clínica Española 2020; in press

Book Chapter: Ward JW, Hinman AR, Alter HJ. Time for the elimination of hepatitis C virus as a global health threat. In Arias IM, Wolkoff AW, Boyer JL, Shafritz DA, Fausto N, Alter HJ, Cohen DE eds. The Liver: Biology and  Pathobiology. 6th edition, West Sussex U

2019 – Reference list of hepatitis publications of the VHPB board members

Hepatitis A and E – Differences and commonalities. Neta Gotlieb, Darius Moradpour, Daniel Shouval. J Hepatol. 2020 Mar;72(3):578-580. doi: 10.1016/j.jhep.2019.05.011. Epub 2019 Jun 5.


Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults

Pierre Van Damme, Marc Dionne, Geert Leroux‐Roels, Olivier Van Der Meeren, Emmanuel Di Paolo, Bruno Salaun, Pemmaraju Surya Kiran, Nicolas Folschweiller

J Viral Hepat. 2019;00:1–10.


Psychosocial and Neurocognitive Factors Associated With Hepatitis C – Implications for Future Health and Wellbeing.

Barreira DP, Marinho RT, Bicho M, Fialho R, Ouakinin SRS.

Front Psychol. 2019 Jan 9;9:2666. doi: 10.3389/fpsyg.2018.02666


Psychosocial and Neurocognitive Factors Associated With Hepatitis C – Implications for Future Health and Wellbeing.

Barreira DP, Marinho RT, Bicho M, Fialho R, Ouakinin SRS.

Front Psychol. 2019 Jan 9;9:2666. doi: 10.3389/fpsyg.2018.02666


Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.

Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, Hutse V.

BMC Public Health. 2019 Jan 8;19(1):39. doi: 10.1186/s12889-018-6347-z.


Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group.

J Viral Hepat. 2019 Mar;26(3):384-396. doi: 10.1111/jvh.13029. Epub 2019 Jan 16.


Effectiveness and impact of the hepatitis B vaccination program in preadolescents in Catalonia 21 years after its introduction.

Borràs E, Urbiztondo L, Carmona G, Jané M, Barrabeig I, Sala MR, Balañà J, Company M, Parrón I, Godoy P, Rius C, Soldevila N, Cabezas C, Domínguez Àthe Working Group for the Study of Hepatitis B in Catalonia.

Vaccine. 2019 Feb 21;37(9):1137-1141. doi: 10.1016/j.vaccine.2019.01.024. Epub 2019 Jan 29.


Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group.

Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.


Genetically similar hepatitis E virus strains infect both humans and wild boars in the Barcelona area, Spain, and Sweden.

Wang H, Castillo-Contreras R, Saguti F, López-Olvera JR, Karlsson M, Mentaberre G, Lindh M, Serra-Cobo J, Norder H.

Transbound Emerg Dis. 2019 Mar;66(2):978-985. doi: 10.1111/tbed.13115. Epub 2019 Feb 14. PubMed PMID: 30597741.


High Frequency of Either Altered Pre-Core StartCodon or Weakened Kozak Sequence in the CorePromoter Region in Hepatitis B Virus A1 Strainsfrom Rwanda.

Norder H, Twagirumugabe T, Said J, Tian Y, Tang KW, Lindh M.

Genes (Basel). 2019 Feb 26;10(3). pii: E182. doi:  10.3390/genes10030182. PubMed PMID: 30813638; PubMed Central PMCID: PMC6471190.


Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.

Reuschel E, Jilg W, Seelbach-Goebel B, Deml L.

PLoS One. 2019 Feb 22;14(2):e0212800. doi: 10.1371/journal.pone.0212800. eCollection 2019.


Immunization against Hepatitis A. Shouval D.

In Enteric hepatitis viruses; Edts SM Lemon and CM Walker pp361-375. Cold Spring Harb Perspect Med. 2018


8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).

Boerekamps A, Vanwolleghem T, van der Valk M, van den Berk GE, van Kasteren M, Posthouwer D, Dofferhoff ASM, van Hoek B, Ramsoekh D, Koopsen J, Schinkel J, Florence E, Arends JE, Rijnders BJ.

J Hepatol. 2019 Mar;70(3):554-557. doi: 10.1016/j.jhep.2018.10.032. Epub 2018 Dec 5. No abstract available.


Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.

Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L, Roudot-Thoraval F; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups.

Hepatology. 2019 Sep;70(3):939-954. doi: 10.1002/hep.30400. Epub 2019 Mar 15.


Hepatitis E virus strains infecting Swedish domestic pigs are unique for each pig farm and remain in the farm for at least 2 years.

Wang H, Karlsson M, Lindberg M, Nyström K, Norder H.

Transbound Emerg Dis. 2019 May;66(3):1314-1323. doi: 10.1111/tbed.13153. Epub 2019 Mar 19. PubMed PMID: 30784199.


HEVnet: a One Health, collaborative, interdisciplinary network and sequence data repository for enhanced hepatitis E virus molecular typing, characterisation and epidemiological investigations.

Mulder AC, Kroneman A, Franz E, Vennema H, Tulen AD, Takkinen J, Hofhuis A, Adlhoch C; Members Of HEVnet.

Euro Surveill. 2019 Mar;24(10). doi: 10.2807/1560-7917.ES.2019.24.10.1800407. PubMed PMID: 30862334; PubMed Central PMCID: PMC6415499.


Estimated cost of comprehensive syringe service program in the United States.

Teshale EH, Asher A, Aslam MV, Augustine R, Duncan E, Rose-Wood A, Ward J, Mermin J, Owusu-Edusei K, Dietz PM.

PLoS One. 2019 Apr 26;14(4):e0216205. doi: 10.1371/journal.pone.0216205. eCollection 2019.


Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.

Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV.

Harm Reduct J. 2019 May 9;16(1):32. doi: 10.1186/s12954-019-0303-9.


Isolation of Subtype 3c, 3e and 3f-Like Hepatitis E Virus Strains Stably Replicating to High Viral Loads in an Optimized Cell Culture System.

Schemmerer M, Johne R, Erl M, Jilg W, Wenzel JJ.

Viruses. 2019 May 28;11(6). pii: E483. doi: 10.3390/v11060483


Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison.

Fraser H, Vellozzi C, Hoerger TJ, Evans JL, Kral AH, Havens J, Young AM, Stone J, Handanagic S, Hariri S, Barbosa C, Hickman M, Leib A, Martin NK, Nerlander L, Raymond HF, Page K, Zibbell J, Ward JW, Vickerman P.

Am J Epidemiol. 2019 May 31. pii: kwz097. doi: 10.1093/aje/kwz097. [Epub ahead of print]


Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.

Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen HLA, Vanwolleghem T.

J Viral Hepat. 2019 Jun;26(6):766-769. doi: 10.1111/jvh.13084. Epub 2019 Mar 14. No abstract available.


The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens.

Wlassow M, Poiteau L, Roudot-Thoraval F, Rosa I, Soulier A, Hézode C, Ortonne V, Pawlotsky JM, Chevaliez S.

J Clin Virol. 2019 Aug;117:80-84. doi: 10.1016/j.jcv.2019.06.007. Epub 2019 Jun 22.


Hepatitis A and E virus infections have different epidemiological patterns in Rwanda.

Twagirumugabe T, Saguti F, Habarurema S, Gahutu JB, Bergström T, Norder H.

Int J Infect Dis. 2019 Sep;86:12-14. doi: 10.1016/j.ijid.2019.06.019. Epub 2019 Jun 22. PubMed PMID: 31238154.


Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.

Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L.

Euro Surveill. 2019 Jul;24(30).


Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.

Mason LMK, Veldhuijzen IK, Duffell E, van Ahee A, Bunge EM, Amato-Gauci AJ, Tavoschi L.

J Viral Hepat. 2019 Jul 22.  


Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion.

Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen H, Vanwolleghem T.

Viruses. 2019 Jul 26;11(8). pii: E687. doi: 10.3390/v11080687.


Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.

Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, Kral A, Page K, Evans J, Zibbell J, Hariri S, Vellozzi C, Nerlander L, Ward JW, Vickerman P.

Addiction. 2019 Jul 15. doi: 10.1111/add.14731. [Epub ahead of print]


Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area.

Tavoschi L, Mason L, Petriti U, Bunge E, Veldhuijzen I, Duffell E.

J Hosp Infect. 2019 Aug;102(4):359-368.  


Biobanking for Viral Hepatitis Research.

Ho E, Van Hees S, Goethals S, Smits E, Huizing M, Francque S, De Winter B, Michielsen P, Vanwolleghem T.

Front Med (Lausanne). 2019 Aug 20;6:183. doi: 10.3389/fmed.2019.00183. eCollection 2019.


Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening programme: The PRECAVIR study.

Rosa-Hezode I, Chousterman M, Costes L, Labourdette C, Elghozi B, Krastinova E, Roudot-Thoraval F.

Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13192. [Epub ahead of print]


Hepatitis E virus genotype 3 is associated with gallstone-related disease.

Karlsson M, Norder H, Bergström M, Park PO, Karlsson M, Wejstål R, Alsiö Å, Rosemar A, Lagging M, Mellgren Å.

Scand J Gastroenterol. 2019 Sep 25:1-5. doi: 10.1080/00365521.2019.1666163. [Epub ahead of print]


Hepatitis E virus genotype 3 strains and a plethora of other viruses detected in raw and still in tap water.

Wang H, Kjellberg I, Sikora P, Rydberg H, Lindh M, Bergstedt O, Norder H.

Water Res. 2019 Sep 30;168:115141. doi: 10.1016/j.watres.2019.115141. [Epub ahead of print]


State of viral hepatitis care in 16 countries of Central and Eastern European Region.

Chkhartishvili N, Holban T, Simonović Babić J, Alexiev I, Matičič M, Kowalska J, Horban A; ECEE Network Group.

Cent Eur J Public Health. 2019 Sep;27(3):212-216. doi: 10.21101/cejph.a5486.


Deaths Associated with Hepatitis C Virus Infection among Residents in 50 States and the District of Columbia, 2016-2017.

Ly KN, Miniño AM, Liu SJ, Roberts H, Hughes EM, Ward JW, Jiles RB.  

Clin Infect Dis. 2019 Oct 5. pii: ciz976. doi: 10.1093/cid/ciz976.


Hepatitis C Pretreatment Profile and Gender Differences: Cognition and Disease Severity Effects.

Barreira DP, Marinho RT, Bicho M, Flores I, Fialho R, Ouakinin S.

Front Psychol. 2019 Oct 15;10:2317. doi: 10.3389/fpsyg.2019.02317.


We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade.

Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF.

J Intern Med. 2019 Nov;286(5):503-525. doi: 10.1111/joim.12972. Epub 2019 Oct 4.


Hepatitis E Virus Shows More Genomic Alterations in Cell Culture than In Vivo.

Sari G, van de Garde MDB, van Schoonhoven A, Voermans JJC, van der Eijk AA, de Man RA, Boonstra A, Vanwolleghem T, Pas SD. Pathogens.

2019 Nov 22;8(4). pii: E255. doi: 10.3390/pathogens8040255.


Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines.

Bonanni P, Boccalini S, Bechini A, Varone O, Matteo G, Sandri F, Gabutti G.

Hum Vaccin Immunother. 2019 Dec 10:1-9. doi: 10.1080/21645515.2019.1688032.


Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018.

Velati C, Romanò L, Pati I, Marano G, Piccinini V, Catalano L, Pupella S, Vaglio S, Veropalumbo E, Masiello F, Pisani G, Grazzini G, Zanetti A, Liumbruno GM.

Blood Transfus. 2019 Nov;17(6):409-417. doi: 10.2450/2019.0245-19. Epub 2019 Dec 11.


Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.

Zarski JP, David-Tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret MN, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-Thoraval F, Nahon P.

Clin Res Hepatol Gastroenterol. 2019 Dec 12. pii: S2210-7401(19)30256-6. doi: 10.1016/j.clinre.2019.11.005.


Prevention of hepatitis A. Daniel Shouval.

In: Viral Hepatitis in Children 2019. Prevention and management. Edt. Mei-Hwei Chang and Kathleen B Schwartz. PP 91-102 Springer


The immunological basis for immunization series: module 18: Hepatitis A. Immunization, Vaccines and Biologicals.

Shouval D and Van Damme P.

Geneve, World Health Organization 2019, https://www.who.int/immunization/documents/ISBN_978-92-51632-7/en/

 

2018 – Reference list of hepatitis publications of the VHPB board members

Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries.
Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R, Veldhuijzen IK.
BMC Infect Dis. 2018 Jan 11;18(1):34. doi: 10.1186/s12879-017-2921-8. No abstract available.
Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States.
Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, Isenhour C, Randall L, Ward JW, Mermin J, Salomon JA, Linas BP.
Clin Infect Dis. 2018 Feb 6. doi: 10.1093/cid/ciy098.
Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.
Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK.
BMC Infect Dis. 2018 Feb 12;18(1):79. doi: 10.1186/s12879-018-2988-x.
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M.
J Hepatol. 2018 Mar;68(3):402-411. doi: 10.1016/j.jhep.2017.10.010.
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.
Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID).
Antiviral Res. 2018 Feb;150:9-14. doi: 10.1016/j.antiviral.2017.12.001.
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3.
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.
Miglietta A, Quinten C, Lopalco PL, Duffell E.
Euro Surveill. 2018 Feb;23(6). doi: 10.2807/1560-7917.ES.2018.23.6.17-00278.
Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
Valerio H, McAuley A, Innes H, Palmateer N, Goldberg DJ, Munro A, Taylor A, Hutchinson SJ.
Int J Drug Policy. 2018 Feb;52:115-122. doi: 10.1016/j.drugpo.2017.12.014.

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.

Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M.

J Hepatol. 2018 Mar;68(3):402-411. doi: 10.1016/j.jhep.2017.10.010. Epub 2018 Jan 8.


Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries. 

Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R, Veldhuijzen IK.

BMC Infect Dis. 2018 Jan 11;18(1):34.  


Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.

Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK.

BMC Infect Dis. 2018 Jan 16;18(1):42.  


The HepHIV 2017 Conference in Malta: joining forces for the earlier diagnosis of HIV and viral hepatitis.

Raben D, Hoekstra M, Sperle I, Amato Gauci AJ, Gauci C, West B, Sullivan A, Lazarus JV, Platteau T, Rockstroh JK; HepHIV Conference Organising Committee and the HIV in Europe Steering Committee.

HIV Med. 2018 Feb;19 Suppl 1:5-10. doi: 10.1111/hiv.12588.


The benefits of hepatitis C virus cure: Every rose has thorns.

Salmon D, Mondelli MU, Maticic M, Arends JE; ESCMID Study Group for Viral Hepatitis.

J Viral Hepat. 2018 Apr;25(4):320-328. doi: 10.1111/jvh.12823. Epub 2018 Feb 19.


Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016).

Aspinall EJ, Hutchinson SJ, Goldberg DJ, Valerio H, Mozalevskis A, Noori T, Duffell E, Tavoschi L.

HIV Med. 2018 Feb;19 Suppl 1:11-15. 


Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.

Miglietta A, Quinten C, Lopalco PL, Duffell E.

Euro Surveill. 2018 Feb;23(6).


Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.

Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK.

BMC Infect Dis. 2018 Feb 12;18(1):79.  


Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.

Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group.

Aliment Pharmacol Ther. 2018 Apr;47(8):1170-1180. doi: 10.1111/apt.14560. Epub 2018 Mar 2.


High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.

Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ.

J Hepatol. 2018 Aug;69(2):293-300. doi: 10.1016/j.jhep.2018.03.007. Epub 2018 Mar 16.


Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyPolaris Observatory Collaborators.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27.


Trends and risk factors of hepatitis A in Catalonia after the introduction of a hepatitis A+B vaccination programme.

Godoy P, Carmona G, Manzanares S, Jané M, Borràs E, Camps N, Álvarez J, Barrabeig I, Sala MR, Rius C, Minguell S, Carol M, Ferras J, Domínguez A, Working Group for the Study of Hepatitis in Catalonia.

J Viral Hepat. 2018 Sep;25(9):1001-1007. doi: 10.1111/jvh.12900. Epub 2018 Apr 26.


Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.


Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network.

Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26.


The Dark Side of the Long-Term Use of Proton Pump Inhibitors in Chronic Liver Disease.

Fernandes SR, Tato Marinho R.

GE Port J Gastroenterol. 2019 Mar;26(2):79-80. doi: 10.1159/000489640. Epub 2018 May 25.


Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.

Lazarus JV, Stumo SR, Harris M, Hendrickx G, Hetherington KL, Maticic M, Jauffret-Roustide M, Tallada J, Simojoki K, Reic T, Safreed-Harmon K; Hep-CORE Study Group.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25052. doi: 10.1002/jia2.25052.


High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles.

Prakash K, Rydell GE, Larsson SB, Andersson M, Norkrans G, Norder H, Lindh M.

Virol J. 2018 May 15;15(1):86. doi: 10.1186/s12985-018-0994-7. PubMed PMID: 29764511; PubMed Central PMCID: PMC5952638.


Viral envelope-specific antibodies in chronic hepatitis B virus infection.

Corti D, Benigni F, Shouval D.

Curr Opin Virol. 2018 Jun;30:48-57. Review


Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.

Velati C, Romanò L, Piccinini V, Marano G, Catalano L, Pupella S, Facco G, Pati I, Tosti ME, Vaglio S, Grazzini G, Zanetti A, Liumbruno GM.

Blood Transfus. 2018 Sep;16(5):422-432. doi: 10.2450/2018.0069-18. Epub 2018 Jun 26.


Assessing the cost-effectiveness of hepatitis C screening strategies in France.

Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y.

J Hepatol. 2018 Oct;69(4):785-792. doi: 10.1016/j.jhep.2018.05.027. Epub 2018 Jul 1.


Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10.


Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19


Hepatitis C virus infection: ‘beyond the liver’.

Arrais de Castro R, Vilas P, Borges-Costa J, Tato Marinho R.

BMJ Case Rep. 2018 Jul 25;2018. pii: bcr-2018-225817. doi: 10.1136/bcr-2018-225817.


Continuous decline of hepatitis E virus seroprevalence in southern Germany despite increasing notifications, 2003–2015.

Mahrt H, Schemmerer M, Behrens G, Leitzmann M, Jilg W, Wenzel JJ.

Emerg Microbes Infect. 2018 Jul 25;7(1):133. doi: 10.1038/s41426-018-0136-8.


Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.

Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Céron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups.

Liver Int. 2019 Jan;39(1):136-146. doi: 10.1111/liv.13921. Epub 2018 Jul 30.


Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.

Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N.

Sci Rep. 2018 Aug 16;8(1):12266. doi: 10.1038/s41598-018-30528-0.


TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands.

Buschow SI, Biesta PJ, Groothuismink ZMA, Erler NS, Vanwolleghem T, Ho E, Najera I, Ait-Goughoulte M, de Knegt RJ, Boonstra A, Woltman AM.

Antiviral Res. 2018 Sep;157:27-37. doi: 10.1016/j.antiviral.2018.06.015. Epub 2018 Jun 28.


Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis.

Bastard JP, Fellahi S, Audureau É, Layese R, Roudot-Thoraval F, Cagnot C, Mahuas-Bourcier V, Sutton A, Ziol M, Capeau J, Nahon P; ANRS CO12 CirVir group.

Eur Cytokine Netw. 2018 Sep 1;29(3):112-120. doi: 10.1684/ecn.2018.0413.


Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M,14, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Liver Int. 2019 Jan;39(1):20-30. doi: 10.1111/liv.13949. Epub 2018 Sep 22.


Distribution of hepatitis B virus genotypes in Europe and clinical implications: a review.

Kmet Lunaček N, Poljak M, Matičič M.

Acta Dermatovenerol Alp Pannonica Adriat. 2018 Sep;27(3):141-146.


Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.

Trabut JB, Barrault C, Charlot H, Carmona D, Bourdel A, Benslimane M, François M, Kini-Matondo W, Causse R, Roudot-Thoraval F, Hézode C.

J Addict Med. 2018 Sep/Oct;12(5):346-352. doi: 10.1097/ADM.0000000000000415.


Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.

Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, Lagging M. 

J Virol. 2018 Sep 12;92(19). pii: e01087-18. doi: 10.1128/JVI.01087-18. Print 2018 Oct 1. PubMed PMID: 30045981; PubMed Central PMCID: PMC6146798.


Hepatitis E Virus Genotype 3 Genomes from RNA-Positive but Serologically Negative Plasma Donors Have CUG as the Start Codon for ORF3.

Norder H, Galli C, Magnil E, Sikora P, Ekvärn E, Nyström K, Magnius LO.

Intervirology. 2018;61(2):96-103. doi: 10.1159/000491926. Epub 2018 Oct 2. PubMed PMID: 30278453; PubMed Central PMCID: PMC6262685.


Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).

Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, Sauce E, Barget N, Bedossa P, Terris B, Selves J, Bioulac-Sage P, Sturm N, Sattonnet C, Nahon P, Roudot-Thoraval F, Ziol M; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1534-1548. doi: 10.1002/hep.29927.


Hepatitis E in Italy: 5 years of national epidemiological, virological and environmental surveillance, 2012 to 2016.

Alfonsi V, Romanò L, Ciccaglione AR, La Rosa G, Bruni R, Zanetti A, Della Libera S, Iaconelli M, Bagnarelli P, Capobianchi MR, Garbuglia AR, Riccardo F, Tosti ME; Collaborating Group.

Euro Surveill. 2018 Oct;23(41). doi: 10.2807/1560-7917.ES.2018.23.41.1700517.


ICTV Virus Taxonomy Profile: Deltavirus.

Magnius L, Taylor J, Mason WS, Sureau C, Dény P, Norder H, Ictv Report Consortium.  

J Gen Virol. 2018 Dec;99(12):1565-1566. doi: 10.1099/jgv.0.001150. Epub 2018 Oct 12. PubMed PMID: 30311870.


Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues.

Chevaliez S, Rodriguez C, Poiteau L, Soulier A, Donati F, Darty-Mercier M, Pioche C, Leroy V, Brodard V, Zoulim F, Brouard C, Larsen C, Semaille C, Roudot-Thoraval F, Pawlotsky JM; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis B Surveillance.

J Viral Hepat. 2019 Feb;26(2):278-286. doi: 10.1111/jvh.13025. Epub 2018 Nov 14.


Reply.

Costentin CE, Layese R, Roudot-Thoraval F, Audureau E, Nahon P; ANRS C012 CirVir group.

Gastroenterology. 2019 Jan;156(1):289-290. doi: 10.1053/j.gastro.2018.11.046. Epub 2018 Nov 23.

Hepatitis A surveillance: sensitivity of two information sources.  

Carmona G, Vilaró M, Ciruela P, Jané M, Giralt L, Ruiz L, Hernández S, Domínguez A, Working Group of the Epidemiological Surveillance Network of Catalonia and Working Group of the Microbiological Reporting System of Catalonia.

BMC Infect Dis. 2018; 18: 633. Published online 2018 Dec 7. doi: 10.1186/s12879-018-3552-4


Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.


Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?

Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F.

PLoS One. 2018 Dec 31;13(12):e0209374. doi: 10.1371/journal.pone.0209374. eCollection 2018.


Hepatitis C Prevention and Control Programme in Catalonia (2018).

Bruguera M, Dominguez A.

http://salutpublica.gencat.cat/web/.content/minisite/aspcat/vigilancia_salut_publica/vih-sida-its/04_Hepatitis_viriques/Plan-Hepatitis-Definitivo_C_DEF_ES.pdf; http://salutpublica.gencat.cat/ca/ambits/vigilancia_salut_publica/vih-sida-its-hv/Hepatitis-viriques/Plans-dactuacio/descripcio/

 

2017 – Reference list of hepatitis publications of the VHPB board members

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ.
Clin Gastroenterol Hepatol. 2017 Sep 22. pii: S1542-3565(17)31162-X. doi: 10.1016/j.cgh.2017.09.027.
State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs – United States, 2015-2016.
Campbell, C. A., L. Canary, N. Smith, E. Teshale, A. B. Ryerson and J. W. Ward.
MMWR Morb Mortal Wkly Rep. 2017; 66(18): 465-469.
Serological survey of hepatitis B immunity in healthcare workers in Catalonia (Spain).
Domínguez A, Urbiztondo L, Bayas JM, Borrás E, Broner S, Campins M, Costa J, Esteve M; Working Group for the Study of the Immune Status in Healthcare Workers of Catalonia.
Hum Vaccin Immunother. 2017 Feb;13(2):435-439. doi: 10.1080/21645515.2017.1264791..
Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions.
Duffell EF, Hedrich D, Mardh O, Mozalevskis A.
Euro Surveill. 2017 Mar 2;22(9). pii: 30476. doi: 10.2807/1560-7917.ES.2017.22.9.30476.
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators.
Lancet Gastroenterol Hepatol. 2017; 2(5): 325-336.
Scaling-up HCV prevention and treatment interventions in rural United States- model projections for tackling an increasing epidemic.
Fraser, H., J. Zibbell, T. Hoerger, S. Hariri, C. Vellozzi, N. K. Martin, A. H. Kral, M. Hickman, J. W. Ward and P. Vickerman.
Addiction. 2017; 2(5): 325-336.
Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
Hezode, C., S. Fourati, S. Chevaliez, G. Scoazec, A. Soulier, A. Varaut, M. Francois, I. Ruiz, F. Roudot-Thoraval, A. Mallat and J. M. Pawlotsky.
Clin Infect Dis. 2017
Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.
Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L.
Epidemiol Infect. 2017 Sep 11:1-13. doi: 10.1017/S0950268817001947.
Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?”.
Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board.
Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056.
Many European countries ‘flying blind’ in their efforts to eliminate viral hepatitis.
Lazarus JV, Safreed-Harmon K, Colombo M, Reic T, Schatz E, van Damme P; ACHIEVE Coalition..
Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):445-446. doi: 10.1038/nrgastro.2017.98..
Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.
Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study Group.
NInt J Drug Policy. 2017 Sep;47:47-50. doi: 10.1016/j.drugpo.2017.05.054.
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.
Lemon SM, Ott JJ, Van Damme P, Shouval D.
J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32278-X. doi: 10.1016/j.jhep.2017.08.034.
Impact of hepatitis C oral therapy in portal hypertension..
Libânio D, Marinho RT.
World J Gastroenterol. 2017 Jul 14;23(26):4669-4674. doi: 10.3748/wjg.v23.i26.4669.
Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers’ vaccination since 1999 and low clinical incidence in all age groups.
Manor Y, Lewis M, Ram D, Daudi N, Mor O, Savion M, Kra-Oz Z, Shemer Avni Y, Sheffer R, Shouval D, Mendelson E.
J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093/infdis/jiw611.
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
Lancet Gastroenterol Hepatol. 2017 Oct 3. pii: S2468-1253(17)30284-4. doi: 10.1016/S2468-1253(17)30284-4.
Third edition of the Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV.
Maticic M.
Germs. 2017 Jun 1;7(2):60. doi: 10.18683/germs.2017.1109.
Late presentation of chronic viral hepatitis for medical care: a consensus definition.
Mauss, S., S. Pol, M. Buti, E. Duffell, C. Gore, J. V. Lazarus, H. L. der Grient, J. Lundgren, A. Mozalevskis, D. Raben, E. Schatz, S. Wiktor and J. K. Rockstroh.
BMC Med. 2017; 15(1): 92.
Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
McDonald, S. A., H. A. Innes, E. Aspinall, P. C. Hayes, M. Alavi, H. Valerio, D. J. Goldberg and S. J. Hutchinson.
J Viral Hepat. 2017; 24(4): 295-303.
High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection.
Mellgren, A., M. Karlsson, M. Karlsson, M. Lagging, R. Wejstal and H. Norder.
J Clin Virol. 2017; 88: 39-45.
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon, P., V. Bourcier, R. Layese, E. Audureau, C. Cagnot, P. Marcellin, D. Guyader, H. Fontaine, D. Larrey, V. De Ledinghen, D. Ouzan, F. Zoulim, D. Roulot, A. Tran, J. P. Bronowicki, J. P. Zarski, V. Leroy, G. Riachi, P. Cales, J. M. Peron, L. Alric, M. Bourliere, P. Mathurin, S. Dharancy, J. F. Blanc, A. Abergel, L. Serfaty, A. Mallat, J. D. Grange, P. Attali, Y. Bacq, C. Wartelle, T. Dao, Y. Benhamou, C. Pilette, C. Silvain, C. Christidis, D. Capron, B. Bernard-Chabert, D. Zucman, V. Di Martino, V. Thibaut, D. Salmon, M. Ziol, A. Sutton, S. Pol and F. Roudot-Thoraval.
Gastroenterology. 2017; 152(1): 142-156.e142.
The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination – Georgia, 2015-2016.
Nasrullah, M., D. Sergeenko, L. Gvinjilia, A. Gamkrelidze, T. Tsertsvadze, M. Butsashvili, D. Metreveli, L. Sharvadze, M. Alkhazashvili, S. Shadaker, J. W. Ward, J. Morgan and F. Averhoff.
MMWR Morb Mortal Wkly Rep 2017; 66(29): 773-776.
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo, A., R. Layese, P. Magistri, M. Gambato, M. Colledan, G. Magini, L. Miglioresi, A. Vitale, G. Vennarecci, C. D. Ambrosio, P. Burra, F. Di Benedetto, S. Fagiuoli, M. Colasanti, G. Maria Ettorre, A. Andreoli, U. Cillo, A. Laurent, S. Katsahian, E. Audureau, F. Roudot-Thoraval and C. Duvoux.
J Hepatol. 2017; 66(3): 552-559.
Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.
Parron, I., C. Planas, P. Godoy, S. Manzanares-Laya, A. Martinez, M. R. Sala, S. Minguell, N. Torner, M. Jane and A. Dominguez.
Hum Vaccin Immunother. 2017; 13(2): 423-427.
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
Polaris Observatory HCV Collaborators.
Lancet Gastroenterol Hepatol. 2017; 2(3): 161-176.
Persistence of immunity 18-19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy.
Romano, L., C. Galli, C. Tagliacarne, M. E. Tosti, C. Velati, L. Fomiatti, M. Chironna, R. C. Coppola, M. Cuccia, R. Mangione, F. Marrone, F. S. Negrone, A. Parlato, C. M. Zotti, A. Mele and A. R. Zanetti.
Hum Vaccin Immunother. 2017; 13(5): 981-985.
Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
Rosenberg, E. S., E. W. Hall, P. S. Sullivan, T. H. Sanchez, K. A. Workowski, J. W. Ward and D. Holtzman.
Clin Infect Dis. 2017
Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations.
Poiteau L, Soulier A, Roudot-Thoraval F, Hézode C, Challine D, Pawlotsky JM, Chevaliez S.
J Clin Virol. 2017 Sep 28;96:64-66. doi: 10.1016/j.jcv.2017.09.012.
Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro.
Rydell GE, Prakash K, Norder H, Lindh M.
Virology. 2017 Sep;509:67-70. doi: 10.1016/j.virol.2017.05.017. Epub 2017 Jun 10.
Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014.
Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C.
Euro Surveill. 2017 Jul 27;22(30). pii: 30582. doi: 10.2807/1560-7917.
Time course of hepatitis E-specific antibodies in adults.
Schemmerer M, Rauh C, Jilg W, Wenzel JJ.
J Clin Virol. 2017 Mar;88:39-45. doi: 10.1016/j.jcv.2017.01.005J Viral Hepat. 2017 Jan;24(1):75-79. doi: 10.1111/jvh.12621.
Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone, J., N. K. Martin, M. Hickman, S. J. Hutchinson, E. Aspinall, A. Taylor, A. Munro, K. Dunleavy, E. Peters, P. Bramley, P. C. Hayes, D. J. Goldberg and P. Vickerman.
Addiction. 2017
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review.
Stuurman, A. L., C. Marano, E. M. Bunge, L. De Moerlooze and D. Shouval.
Hum Vaccin Immunother. 2017; 13(3): 724-736.
Hepatitis B virus strains from Rwandan blood donors are genetically similar and form one clade within subgenotype A1.
Twagirumugabe, T., G. Swaibu, T. D. Walker, M. Lindh, J. B. Gahutu, T. Bergstrom and H. Norder.
BMC Infect Dis. 2017; 17(1): 32.
Low prevalence of hepatitis C virus RNA in blood donors with anti-hepatitis C virus reactivity in Rwanda.
Twagirumugabe T, Swaibu G, Bergström T, Walker TD, Gahutu JB, Norder H.
Transfusion. 2017 Oct;57(10):2420-2432. doi: 10.1111/trf.14204.
Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions.
Zuin M, Caserta C, Romanò L, Mele A, Zanetti A, Cannatelli R, Giorgini A, Tagliacarne C, Amante A, Marcucci F, Battezzati PM.
Eur J Clin Microbiol Infect Dis 2017; 36: 479-485.
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy.
Zanetti, A., M. G. Desole, L. Romano, A. d’Alessandro, M. Conversano, G. Ferrera, M. G. Panico, A. Tomasi, G. Zoppi, M. Zuliani, S. Thomas, B. Soubeyrand, C. Eymin and S. Lockhart.
Vaccine 2017; 35(32): 4034-4040.

Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review.

Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D.

Hum Vaccin Immunother. 2017 Mar 4;13(3):724-736. Review.


Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review.

Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Byström E, Lopalco P; ECDC HAV Expert Panel.

Lancet Infect Dis. 2017 Oct;17(10):e306-e319. doi: 10.1016/S1473-3099(17)30392-4. Epub 2017 Jun 20.


Third edition of the Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV. Matičič M. Germs. 2017 Jun 1;7(2):60. doi: 10.18683/germs.2017.1109. eCollection 2017 Jun.


Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study Group. Int J Drug Policy. 2017 Sep;47:47-50. doi: 10.1016/j.drugpo.2017.05.054. Epub 2017 Jul 6.


Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ.

Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.


Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3


Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.


Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.

Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID).

Antiviral Res. 2018 Feb;150:9-14. doi: 10.1016/j.antiviral.2017.12.001. Epub 2017 Dec 5.


Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012.

da Rocha MC, Marinho RT, Rodrigues T.

GE Port J Gastroenterol. 2018 Apr;25(3):123-131. doi: 10.1159/000484868. Epub 2017 Dec 6.


Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy.

Bini C, Grazzini M, Chellini M, Mucci N, Arcangeli G, Tiscione E, Bonanni P.

Hum Vaccin Immunother. 2018 Feb 1;14(2):450-455. doi: 10.1080/21645515.2017.1398297. Epub 2017 Dec 19.


Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.

Fourati S, Guedj J, Chevaliez S, Nguyen THT, Roudot-Thoraval F, Ruiz I, Soulier A, Scoazec G, Varaut A, Poiteau L, Francois M, Mallat A, Hézode C, Pawlotsky JM.

Aliment Pharmacol Ther. 2018 Mar;47(5):665-673. doi: 10.1111/apt.14478. Epub 2017 Dec 22.

2016 – Reference list of hepatitis publications of the VHPB board members

2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.
Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, Volant J, Dhumeaux D, Yazdanpanah Y; Viral Hepatitis Testing Experts group.
Liver Int. 2016; 36(10):1442-9. doi: 10.1111/liv.13135.
Key Role of Sequencing to Trace Hepatitis A Viruses Circulating in Italy During a Large Multi-Country European Foodborne Outbreak in 2013.
Bruni R, Taffon S, Equestre M, Chionne P, Madonna E, Rizzo C, Tosti ME, Alfonsi V, Ricotta L, De Medici D, Di Pasquale S, Scavia G, Pavoni E, Losio MN, Romanò L, Zanetti AR, Morea A, Pacenti M, Palù G, Capobianchi MR, Chironna M, Pompa MG, Ciccaglione AR; Italian National Task Force on Hepatitis A.
PLoS One 11(2): e0149642.
Markers of Protection in Children and Adolescents Six to Fourteen Years After Primary Hepatitis B Vaccination in Real Life: A Pilot Study.
Brunskole Hummel I, Huber B, Wenzel JJ, Jilg W.
Pediatr Infect Dis J. 2016; 35(3):286-91. doi: 10.1097/INF.0000000000000994.
Characteristics of immune memory 10-15 years after primary hepatitis B vaccination.
Brunskole Hummel I, Zitzmann A, Erl M, Wenzel JJ, Jilg W.
Vaccine. 2016 Jan 27;34(5):636-642. doi: 10.1016/j.vaccine.2015.12.033.
Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.
Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hézode C, Pawlotsky JM.
Clin Microbiol Infect. 2016; pii: S1198-743X(16)00025-2. doi: 10.1016/j.cmi.2016.01.009.
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O’Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B.
Front Pharmacol. 2016; 7: 197.
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y.
J Viral Hepat. 2016; 23(10):767-79. doi: 10.1111/jvh.12546.
Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns.
Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvåg BK, Sundin CG, Brytting M, Esbjörnsson J, Mild M.
Infect Ecol Epidemiol. 2016; 6:30670. doi: 10.3402/iee.v6.30670. eCollection 2016.
Hepatitis E in Israel: A nation-wide retrospective study.
Erez-Granat O, Lachish T, Daudi N, Shouval D, Schwartz E.
World J Gastroenterol. 2016; 22(24): 5568-5577.
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).
Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.
Hepatology. 2016; 64(4):1136-47. doi: 10.1002/hep.28702.
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F; ANRS CO12 CirVir Study Group.
Gastroenterology. 201; pii: S0016-5085(16)35070-3. doi: 10.1053/j.gastro.2016.09.009.
Outbreaks of hepatitis A associated with immigrants travelling to visit friends and relatives.
Godoy P, Broner S, Manzanares-Laya S, Martínez A, Parrón I, Planas C, Sala-Farré MR, Minguell S, de Olalla PG, Jané M, Domínguez A, Working Group for the Study of Hepatitis A in Catalonia.
Journal of Infection 2016; 72:112-129.
National Progress Toward Hepatitis C Elimination – Georgia, 2015-2016.
Gvinjilia L, Nasrullah M, Sergeenko D, Tsertsvadze T, Kamkamidze G, Butsashvili M, Gamkrelidze A, Imnadze P, Kvaratskhelia V, Chkhartishvili N, Sharvadze L, Drobeniuc J, Hagan L, Ward JW, Morgan J, Averhoff F.
MMWR Morb Mortal Wkly Rep. 2016; 65(41): 1132-1135.
Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C, Pawlotsky JM.
Hepatology. 2016; doi: 10.1002/hep.28491.
Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
Hutin, Y. J. and S. Z. Wiktor.
Gut.2016.
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
Isakov V, Zhdanov K, Kersey K, Svarovskaia E, Massetto B, Zhu Y, Knox SJ, Bakulin I, Chulanov V.
Antivir Ther. 2016; 21(8): 671-678.
Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia.
Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA; P08160 Trial Investigators.
World J Hepatol. 2016 Feb 28;8(6):331-9. doi: 10.4254/wjh.v8.i6.331.
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype 1 and 3 HCV infection: results from a Russian Phase IIIb study.
Isakov V, Zhdanov K, Kersey K, Svarovskaia E, Massetto B, Zhu Y, Knox SJ, Bakulin I, Chulanov V.
Antivir Ther. 2016 Jul 4. doi: 10.3851/IMP3065.
The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.
Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, Krajden M, Ward JW, Harrigan PR, Montaner JS, Poon AF.
Lancet Infect Dis. 2016; 16(6): 698-702.
The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
Klevens RM, Canary L, Huang X, Denniston MM, Yeo AE, Pesano RL, Ward JW, Holmberg S.
Clin Infect Dis. 2016; 63(8): 1049-1055.
Trends in Injection Drug Use Among High School Students, U.S., 1995-2013.
Klevens RM, Jones SE, Ward JW, Holtzman D, Kann L.
Am J Prev Med. 2016 Jan;50(1):40-6. doi: 10.1016/j.amepre.2015.05.026. Epub 2015 Aug 24.
Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission – United States and Kentucky, 2011-2014.
Koneru A, Nelson N, Hariri S, Canary L, Sanders KJ, Maxwell JF, Huang X, Leake JA, Ward JW, Vellozzi C.
MMWR Morb Mortal Wkly Rep. 1016; 65(28): 705-710.
Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers’ vaccination since 1999 and low clinical incidence in all age groups.
Manor Y, Lewis M, Ram D, Daudi N, Mor O, Savion M, Kra-Oz Z, Shemer Avni Y, Sheffer R, Shouval D, Mendelson E.
J Infect Dis. 2016.
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care.
Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators.
BMC Infect Dis. 2016; 16(1): 565.
Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection – Cherokee Nation, 2012-2015.
Mera J, Vellozzi C, Hariri S, Carabin H, Drevets DA, Miller A, Reilley B, Essex W, Gahn D, Lyons L, Leston J, Ward JW.
MMWR Morb Mortal Wkly Rep. 2016; 65(18): 461-466.
Requirements for global elimination of hepatitis B: a modelling study.
Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB.
Lancet Infect Dis. 2016; 16(12): 1399-1408.
Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.
Norder H, Karlsson M, Mellgren Å, Konar J, Sandberg E, Lasson A, Castedal M, Magnius L, Lagging M.
J Clin Microbiol. 2016; 54(3):549-55. doi: 10.1128/JCM.02343-15.
Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. 591 kB (.pdf)
Orlando Mayorga, Silja Bühler, Veronika K. Jaeger, Seraina Bally, Christoph Hatz, Gert Frösner, Ulrike Protzer, Pierre Van Damme, Matthias Egger and Christian Herzog.
JID; 2016, 214:1498-1506
Time trends in pediatric hospitalizations for hepatitis A in Greece (1999-2013): Assessment of the impact of universal infant immunization in 2008.
Papaevangelou V, Alexopoulou Z, Hadjichristodoulou C, Kourlamba G, Katsioulis A, Theodoridou K, Spoulou V, Theodoridou M.
Hum Vaccin Immunother. 2016;12(7):1852-6. doi: 10.1080/21645515.2016.1151589.
Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.
Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A.
J Viral Hepat. 2016; Suppl 1:1-12. doi: 10.1111/jvh.12493.
Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
Poiteau L, Soulier A, Rosa I, Roudot-Thoraval F, Hézode C, Pawlotsky JM, Chevaliez S.
J Viral Hepat. 2016; doi: 10.1111/jvh.12501.
Markers for Ongoing or Previous Hepatitis E Virus Infection Are as Common in Wild Ungulates as in Humans in Sweden.
Roth A, Lin J, Magnius L, Karlsson M, Belák S, Widén F, Norder H.
Viruses. 2016;8(9). pii: E259.
Hepatitis C virus outbreak in a haemodialysis unit: learning from failures.
Senatore S, Galli C, Conti A, Faccini M, Cantoni S, Ciconali G, Mainardi G, Lamberti A, Dighera R, Radice Trolli F, Oggioni C, Angelini Sironi L, Cozzolino M, Zanetti AR, Romanò L.
J Hosp Infect. 2016; 94(3): 249-252.
Acute Hepatitis B After the Implementation of Universal Vaccination in Italy: Results From 22 Years of Surveillance (1993-2014).
Tosti ME, Alfonsi V, Lacorte E, Mele A, Galli C, Zanetti AR, Romanò L; SEIEVA Collaborating Group.
Clin Infect Dis. 2016; 62(11): 1412-1418.
Long-term Protection After Hepatitis B Vaccine.
Van Damme P.
J Infect Dis. 2016; pii: jiv750. [Epub ahead of print] No abstract available.
County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States.
Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, Jones CM, Flanagan BE, Siddiqi AE, Iqbal K, Dent AL, Mermin JH, McCray E, Ward JW, Brooks JT.
J Acquir Immune Defic Syndr. 2016; 73(3): 323-331.
Building the evidence base to eliminate hepatitis B and C as public health threats.
Ward, J. W.
Lancet Infect Dis. 2016; 16(12): 1314-1316.
Global Elimination of Hepatitis C Virus.
Ward, J. W.
Gastroenterol Hepatol (N Y). 2016; 12(10): 632-635.
Strategies for Expanding Access to HBV and HCV Testing and Care in the United States: The CDC Hepatitis Testing and Linkage to Care Initiative, 2012-2014.
Ward, J. W.
Public Health Rep. 2016; 131 Suppl 2: 1-4.
The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts.
Wiktor, S. Z. and Y. J. Hutin
Lancet. 2016; 388(10049): 1030-1031.
Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
Weir A, McLeod A, Innes H, Valerio H, Aspinall EJ, Goldberg DJ, Barclay ST, Dillon JF, Fox R, Fraser A, Hayes PC, Kennedy N, Mills PR, Stanley AJ, Aitken C, Gunson R, Templeton K, Hunt A, McIntyre P, Hutchinson SJ.
Drug Alcohol Depend. 2016;165:53-60. doi: 10.1016/j.drugalcdep.2016.05.012.

Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.

Parrón I, Planas C, Godoy P, Manzanares-Laya S, Martínez A, Sala MR, Minguell S, Torner N, Jané M, Domínguez A; Working Group for the Study of Hepatitis A in Catalonia.

Hum Vaccin Immunother. 2017 Feb;13(2):423-427. doi: 10.1080/21645515.2017.1264798. Epub 2016 Dec 7.


Serological survey of hepatitis B immunity in healthcare workers in Catalonia (Spain).

Domínguez A, Urbiztondo L, Bayas JM, Borrás E, Broner S, Campins M, Costa J, Esteve M; Working Group for the Study of the Immune Status in Healthcare Workers of Catalonia.

Hum Vaccin Immunother. 2017 Feb;13(2):435-439. doi: 10.1080/21645515.2017.1264791. Epub 2016 Dec 27.

2015 – Reference list of hepatitis publications of the VHPB board members

Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2.
Gane E, Kershenobich D, Seguin-Devaux C, …, Chulanov V, et al.
J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. doi: 10.1111/jvh.12352.
The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – volume 2.
Hatzakis A, Chulanov V, et al.
J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. doi: 10.1111/jvh.12351.
Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2.
Saraswat V, Norris S, de Knegt RJ, …, Chulanov V, et al.
J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. doi: 10.1111/jvh.12350.
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.
Gut. 2015 Nov;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. Review.
Global policy and access to new hepatitis C therapies for people who inject drugs.
Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME.
Int J Drug Policy. 2015 Nov;26(11):1064-71. doi: 10.1016/j.drugpo.2015.05.008. Epub 2015 Jun 2.
Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, Londeix P, Forette C, Momenghalibaf A, Verster A, Swan T.
Int J Drug Policy. 2015 Nov;26(11):1088-93. doi: 10.1016/j.drugpo.2015.05.004. Epub 2015 May 18.
Deciding who should be treated for hepatitis C infection in a rapidly changing therapeutic landscape.
Wiktor SZ.
Hepatology. 2015 Jul;62(1):13-5. doi: 10.1002/hep.27810. Epub 2015 May 29. No abstract available.
Where next for hepatitis B and C surveillance?
Wiktor SZ.
J Viral Hepat. 2015 Jul;22(7):571-3. doi: 10.1111/jvh.12400. Epub 2015 Mar 6.
Substantial decline in hepatitis B virus infections following vaccine introduction in Tajikistan.
Khetsuriani N, Tishkova F, Jabirov S, Wannemuehler K, Kamili S, Pirova Z, Mosina L, Gavrilin E, Ursu P, Drobeniuc J.
Vaccine. 2015 Jul 31;33(32):4019-24. doi: 10.1016/j.vaccine.2015.05.092. Epub 2015 Jun 10.
Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J, Hoestlandt C, D Clark A, Baxter L, Felix Garcia AG, Mounaud B, Mosina L.
Vaccine. 2015 May 7;33 Suppl 1:A34-9. doi: 10.1016/j.vaccine.2014.12.073.
Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3.
Liakina V, Hamid S, Tanaka J, Olafsson S, …, Matičič M, …
J Viral Hepat. 2015 Dec;22 Suppl 4:4-20. doi: 10.1111/jvh.12475.
The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm – volume 3.
Sibley A, Han KH, Abourached A,…, Matičič M, …
J Viral Hepat. 2015 Dec;22 Suppl 4:21-41. doi: 10.1111/jvh.12476.
Strategies to manage hepatitis C virus infection disease burden – volume 3.
Alfaleh FZ, Nugrahini N, Matičič M, et al.
J Viral Hepat. 2015 Dec;22 Suppl 4:42-65. doi: 10.1111/jvh.12474.
Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program.
Martínez A, Broner S, Sala MR, Manzanares-Laya S, Godoy P, Planas C, Minguell S, Torner N, Jané M, Domínguez A.
Hum Vaccin Immunother. 2015;11(1):192-7. doi: 10.4161/hv.35861.
Acute hepatitis E virus in pregnant women in Israel and in other industrialized countries.
Lachish T, Erez O, Daudi N, Shouval D, Schwartz E.
J Clin Virol. 2015 Oct 19;73:20-24.
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
Pierre N, Lescat M, Layese R, …, Roudot-Thoraval F, for the ANRS CO12 CirVir and Microcir Groups.
gutjnl-2015-310275.
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.
Ward JW,Mermin JH.
N Engl J Med. 2015 Dec 31;373(27):2678-80. doi: 10.1056/NEJMe1513245. Epub 2015 Nov 17.
Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers.
Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW.
MMWR Morb Mortal Wkly Rep. 2015 Oct 9;64(39):1118-20. doi: 10.15585/mmwr.mm6439a6.
Launch of a Nationwide Hepatitis C Elimination Program–Georgia, April 2015.
Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, Chokheli M, Drobeniuc J, Hagan L, Harris AM, Jiqia T, Kasradze A, Ko S, Qerashvili V, Sharvadze L, Tskhomelidze I, Kvaratskhelia V, Morgan J, Ward JW, Averhoff F.
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806.
Cost-effectiveness of strategies for testing current hepatitis C virus infection.
Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG.
Hepatology. 2015 Nov;62(5):1396-404. doi: 10.1002/hep.27966. Epub 2015 Aug 25.
Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012.
Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, Blankenship S, Ward JW, Holtzman D; Centers for Disease Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8.
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW.
Clin Infect Dis. 2015 Jul 15;61(2):157-68. doi: 10.1093/cid/civ220.
Making hepatitis E a vaccine-preventable disease.
Teshale E, Ward JW.
N Engl J Med. 2015 Mar 5;372(10):899-901. doi: 10.1056/NEJMp1415240.
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.
Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD.
Hepatology. 2015 Jun;61(6):1860-9. doi: 10.1002/hep.27736.
Estimates on HCV disease burden worldwide – filling the gaps.
Wedemeyer H, Dore GJ, Ward JW.
J Viral Hepat. 2015 Jan;22 Suppl 1:1-5. doi: 10.1111/jvh.12371.
Enhanced surveillance of hepatitis C in the EU, 2006-2012.
Duffell EF, van de Laar MJ, Amato-Gauci AJ.
J Viral Hepat. 2015 Jul;22(7):590-5.
Enhanced surveillance of hepatitis B in the EU, 2006-2012.
Duffell EF, van de Laar MJ, Amato-Gauci AJ.
J Viral Hepat. 2015 Jul;22(7):581-9.
Lessons learnt over two decades of vaccination against hepatitis B in Italy.
Romano’ L, Galli C, Zanetti ARA..
Journal of Preventive Medicine and Hygiene, 2015; 56:E12-14.
Outbreaks of hepatitis A associated with immigrants travelling to visit friends and relatives.
Godoy P, Broner S, Manzanares-Laya S, Martínez A, Parrón I, Planas C, Sala-Farré MR, Minguell S, de Olalla PG, Jané M, Dominguez A; Working Group for the Study of Hepatitis A in Catalonia.
J Infect. 2015 Sep 21. pii: S0163-4453(15)00284-4. doi: 10.1016/j.jinf.2015.09.006.
Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009.
Duffell EF, van de Laar MJ.
Euro surveillance : bulletin Europeen sur les maladies transmissibles Apr 2;20(13):17-24
Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection.
Valerio H, Goldberg DJ, Lewsey J, Weir A, Allen S, Aspinall EJ, Barclay ST, Bramley P, Dillon JF, Fox R, Fraser A, Hayes PC, Innes H, Kennedy N, Mills PR, Stanley AJ, Hutchinson SJ.
Drug Alcohol Depend. 2015 Sep 1;154:125-31. doi: 10.1016/j.drugalcdep.2015.06.032.
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland’s experience.
Hutchinson SJ, Dillon JF, Fox R, McDonald SA, Innes HA, Weir A, McLeod A, Aspinall EJ, Palmateer NE, Taylor A, Munro A, Valerio H, Brown G, Goldberg DJ.
Int J Drug Policy. 2015 Nov;26(11):1041-9. doi: 10.1016/j.drugpo.2015.05.019.
Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland.
Prevost TC, Presanis AM, Taylor A, Goldberg DJ, Hutchinson SJ, De Angelis D.
Addiction. 2015 Aug;110(8):1287-300. doi: 10.1111/add.12948. 
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ.
Hepatology. 2015 Aug;62(2):355-64. doi: 10.1002/hep.27766
Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoove M, Wiktor SZ, Hutchinson S.
Eur J Epidemiol. 2015 Feb;30(2):115-29. doi: 10.1007/s10654-014-9958-4.
Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?
Innes H, Goldberg D, Dillon J, Hutchinson SJ.
Gut. 2015 Nov;64(11):1800-9. doi: 10.1136/gutjnl-2014-308166.
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M.
J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338
Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, Amin J, Goldberg DJ, Innes H, Law M, Walter SR, Krajden M, Dore GJ.
J Hepatol. 2015 Feb;62(2):269-77. doi: 10.1016/j.jhep.2014.09.001.
What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ.
J Hepatol. 2015 Feb;62(2):262-8. doi: 10.1016/j.jhep.2014.08.046.
HCV treatment as prevention in prison: key issues.
Martin NK, Vickerman P, Goldberg D, Hickman M.
Hepatology. 2015 Jan;61(1):402-3. doi: 10.1002/hep.27194
Prevalence of HBV and HCV among outpatients in the Plovdiv region of Bulgaria, 2010-2011.
Kevorkyan A1, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M.
J Med Virol. 2015 Mar;87(3):401-6. doi: 10.1002/jmv.24065.
Diagnostic performance of five assays for anti-HEV IgG and IgM in a large cohort study.
Norder H, Karlsson M, Mellgren Å, Konar J, Sandberg E, Lasson A, Castedal M, Magnius L, Lagging M.
J Clin Microbiol. 2015 Dec 9. pii: JCM.02343-15.
Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report.
Waldenström J, Castedal M, Konar J, Karason K, Lagging M, Norder H.
J Med Case Rep. 2015 Aug 26;9:180. doi: 10.1186/s13256-015-0655-z.
Incidence of Hepatitis E Antibodies in Swedish Lung Transplant Recipients.
Magnusson J, Norder H, Riise GC, Andersson LM, Brittain-Long R, Westin J.
Transplant Proc. 2015 Jul-Aug;47(6):1972-6. doi: 10.1016/j.transproceed.2015.04.092.
High prevalence of hepatitis e virus in Swedish moose–a phylogenetic characterization and comparison of the virus from different regions.
Lin J, Karlsson M, Olofson AS, Belák S, Malmsten J, Dalin AM, Widén F, Norder H.
PLoS One. 2015 Apr 23;10(4):e0122102. doi: 10.1371/journal.pone.0122102.
High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment.
Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T.
Hepatol Res. 2015 Feb 16. doi: 10.1111/hepr.12505.
Three decades of hepatitis B control with vaccination.
Meireles LC, Marinho RT, Van Damme P.
World J Hepatol. 2015 Aug 28;7(18):2127-32. doi: 10.4254/wjh.v7.i18.2127.
Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks.
Mellou K, Sideroglou T, Papaevangelou V, Katsiaflaka A, Bitsolas N, Verykouki E, Triantafillou E, Baka A, Georgakopoulou T, Hadjichristodoulou C.
PLoS One. 2015 Jan 15;10(1):e0116939. doi: 10.1371/journal.pone.0116939
Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME.
J Antimicrob Chemother. 2015 Feb;70(2):396-404. doi: 10.1093/jac/dku404
Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring.
Soulier A, Poiteau L, Rosa I, Hézode C, Roudot-Thoraval F, Pawlotsky JM, Chevaliez S.
J Infect Dis. 2015 Sep 2. pii: jiv423
Cure of hepatitis C.
Roudot-Thoraval F.
Acta Med Port. 2015 Jan-Feb;28(1):10-1
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D, Roggendorf H, Roggendorf M.
Med Microbiol Immunol. 2015 Feb;204(1):57-68. doi: 10.1007/s00430-014-0374-x.
Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions.
Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N.
Vaccine. 2015 Oct 13;33(42):5723-7. doi: 10.1016/j.vaccine
Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine.
Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P.
Pediatr Infect Dis J. 2015 Apr;34(4):e85-91. doi: 10.1097/INF.0000000000000616.
Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers.
Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW.
MMWR Morb Mortal Wkly Rep. 2015 Oct 9;64(39):1118-20. doi: 10.15585/mmwr.mm6439a6.
Launch of a Nationwide Hepatitis C Elimination Program–Georgia, April 2015.
Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, Chokheli M, Drobeniuc J, Hagan L, Harris AM, Jiqia T, Kasradze A, Ko S, Qerashvili V, Sharvadze L, Tskhomelidze I, Kvaratskhelia V, Morgan J, Ward JW, Averhoff F.
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806.
Clinical, epidemiological and virological features of acute hepatitis B in Italy.
Zuccaro O, Romanò L, Mele A, Mariano A, Clementi M, Tosti ME, Taliani G, Galli C, Zanetti AR, Spada E; Study Group.
Infection. 2015 Aug;43(4):431-41. doi: 10.1007/s15010-015-0747-0
Hepatitis B vaccination.
Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR.
Hum Vaccin Immunother. 2015;11(1):53-7. doi: 10.4161/hv.34306.
The Disease Burden of Hepatitis C in Belgium : An update of a realistic disease control strategy.
Stärkel P, Vandijck D, Laleman W, Van Damme P, Moreno C, Blach S, Razavi H, Van Vlierberghe H.
Acta Gastroenterol Belg. 2015 Jun;78(2):228-32.
Coverage of the expanded program on immunization in Vietnam: Results from 2 cluster surveys and routine reports.
Nguyen TD, Dang AD, Van Damme P, Nguyen CV, Duong HT, Goossens H, Theeten H, Leuridan E.
Hum Vaccin Immunother. 2015;11(6):1526-33.
Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV-positive adults from Gabon (Central Africa).
Rouet F, Deleplancque L, Mboumba BB, Sica J, Mouinga-Ondémé A, Liégeois F, Goudeau A, Dubois F, Gaudy-Graffin C.
PLoS One. 2015 Jan 24;10(1):e0116975. doi: 10.1371/journal.pone.0116975
Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.
Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F.
PLoS One. 2015 Jun 24;10(6):e0125214. doi: 10.1371/journal.pone.0125214.
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.
Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Müllhaupt B, Razavi H, Semela D.
Swiss Med Wkly. 2015 Dec 4;145:w14221. doi: 10.4414/smw.2015.14221.
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M.
PLoS One. 2015 May 14;10(5):e0126984. doi: 10.1371/journal.pone.0126984. 

Hepatotoxicity of herbal and dietary supplements: an update.

Stickel F, Shouval D.

Arch Toxicol. 2015 Jun;89(6):851-65. doi: 10.1007/s00204-015-1471-3. Review.

2014 – Reference list of hepatitis publications of the VHPB board members

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study.
BN Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338.
Determinants of vaccination coverage and adherence to the Greek national immunization program among infants aged 2-24 months at the beginning of the economic crisis (2009-2011).
Vassiliki P, Ioanna K, Artemis V, Eleni K, Aglaia Z, Attilakos A, Maria T, Dimitris K.
BMC Public Health. 2014 Nov 20;14:1192.
[Molecular epidemiology of hepatitis C in centers of hemodialysis in St. Petersburg].
Mukomolov SL, Tallo T, Sinaĭskaia EV, Kislyĭ PN, Trifonova GF, Gerasimova VV, Norder H.
Zh Mikrobiol Epidemiol Immunobiol. 2014 Nov-Dec;(6):27-34.
Detection of pathogenic viruses in sewage provided early warnings of hepatitis A virus and norovirus outbreaks.
Hellmér M, Paxéus N, Magnius L, Enache L, Arnholm B, Johansson A, Bergström T, Norder H.
Appl Environ Microbiol. 2014 Nov;80(21):6771-81. doi: 10.1128/AEM.01981-14. 
A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
Maticic M, Luznik Z, Stepec S, Popovic P, Snedec N, Poljak M, Stanisavljevic D.
J Clin Gastroenterol. 2014 May-Jun;48(5):464-5. doi: 10.1097/MCG.0000000000000037
Incentives and barriers regarding immunization against influenza and hepatitis of health care workers.
FitzSimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P.
Vaccine. 2014 Aug 27;32(38):4849-54. doi: 10.1016/j.vaccine.2014.06.072
Focusing on the past, present, and future of hepatology.
Shouval D, Friedman SL  
J Hepatol. 2014 Dec;61(6):1196-8. doi: 10.1016/j.jhep.2014.08.039.
Risky business-the real life of the unresolved HCV therapy.
Ferreira AO, Marinho RT.
Gastroenterology. 2014 Nov;147(5):1185-6. doi: 10.1053/j.gastro.2014.07.058.
Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, et al.
J Antimicrob Chemother 2014. DOI: 10.1007/s10654-014-9958-4
Duffell EF, van de Laar MJ, Amato-Gauci AJ .
Eur J Epidemiol 2014. DOI: 10.1111/jvh.12367
Duffell EF, van de Laar MJ, Amato-Gauci AJ .
J Viral Hepat 2014. DOI:10.1111/jvh.12364
Ford N, Swan T, Beyer P, Hirnschall G, Easterbrook P, Wiktor S.
J Hepatol 2014,61:S132-S138. DOI: 10.1016/j.jhep.2014.09.019
Innes H, Goldberg D, Dillon J, Hutchinson SJ.
Gut 2014. DOI: 10.1093/jac/dku404
Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P.
Pediatr Infect Dis J 2014. DOI: 10.1136/gutjnl-2014-308166
Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME.
J Antimicrob Chemother 2014. DOI: 10.1093/jac/dku404
Martin NK, Foster GR, Vilar J, Ryder S, M EC, Gordon F, Dillon JF, …Goldberg DJ… Hickman M.et al.
J Viral Hepat 2014 DOI: 10.1111/jvh.12338
Schnier C, Wallace L, Tempelton K, Aitken C, Gunson RN,… Goldberg D , Hutchinson S.
Epidemiol Infect 2014,142:2121-2130. DOI:10.1017/s0950268813003105
Wenzel JJ, Sichler M, Schemmerer M, Behrens G, Leitzmann MF, Jilg W.,
Hepatology 2014,60:1180-1186. DOI: 10.1002/hep.27244
Martinez, A., Broner, S., Sala, M. R., Manzanares-Laya, S., Godoy, P., … Dominguez, A., Group, T. W. and Hepatitis, A. In Catalonia F. T.
Human vaccines & immunotherapeutics 2014 Aug 19;11(1). ISSN:2164-554X (Electronic)
McDonald, S. A., Innes, H. A., Hayes, P. C., … Goldberg, D. J., … Bhattacharyya, D. and Hutchinson, S. J.et. al.
Journal of hepatology 2014 Sep 4. doi:10.1016/j.jhep.2014.08.046
Levi, M., Ahmad, A., Bechini, A., Boccalini, S., Nguyen, Q., Veldhuijzen, I., Richardus, J. H., Reintjes, R. and Bonanni, P.
Vaccine 2014 Sep 30. doi:10.1016/j.vaccine.2014.09.042
Krawczyk, A., Ludwig, C., Jochum, C., Fiedler, M., Heinemann, F. M., Shouval, D., Roggendorf, M., Roggendorf, H. and Lindemann, M.
Vaccine 2014 Sep 3;32(39):5077-82. doi:10.1016/j.vaccine.2014.06.076
Kautz, A., Chavdarova, L. and Walker, M. ELPA.
BMC infectious diseases 2014;14 Suppl 6:S3 doi:10.1186/1471-2334-14-s6-s3
Itani, T., Jacobsen, K. H., Nguyen, T. and Wiktor, S. Z..
Vaccine 2014 Sep 16. doi:10.1016/j.vaccine.2014.09.006
Ward, JW.
Hepatology 2014 Aug 18. doi:10.1002/hep.27377
Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A,… Ward, JW.. et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Aug 11. doi:10.1093/cid/ciu643/td>
Wenzel JJ, Sichler M, Schemmerer M, Behrens G, Leitzmann MF, Jilg W.
Hepatology 2014 Jun 9. doi:10.1002/hep.27244
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C,…Marinho RT, et al.
N Engl J Med 2014,370:1983-1992. doi: 10.1056/NEJMoa1402338
Beckett GA, Ramirez G, Vanderhoff A, Nichols K, Chute SM, Wyles DL, …. Ward, J.W…et al.
MMWR Morbidity and mortality weekly report 2014 May 9;63(18):399-401. ISSN: 1545-861X
Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, …. Ward, J.W…et al.
MMWR Morbidity and mortality weekly report 2014 May 9;63(18):393-8. ISSN: 1545-861X
Shouval D.
J Hepatol 2014. May 15. doi: 10.1016/j.jhep.2014.05.012
Wedemeyer H, Duberg AS … Lavanchy D, Marinho R T, Roudot-Thoraval F,Van Damme P, et al.
J Viral Hepat 2014,21 Suppl 1:60-89. doi: 10.1111/jvh.12249
Razavi H, Waked I, … Lavanchy D, Marinho R T, Roudot-Thoraval F,Van Damme P, et al.
J Viral Hepat 2014,21 Suppl 1:34-59. doi: 10.1111/jvh.12248
McDonald SA, Hutchinson SJ, Innes HA, Allen S, Bramley P, Bhattacharyya D, … Goldberg DJ, et al.
J Viral Hepat 2014,21:366-376 doi: 10.1111/jvh.12153
Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P.
Clin Microbiol Infect 2014,20 Suppl 5:19-24.
Bruggmann P, Berg T, …Lavanchy D, Marinho R T, Roudot-Thoraval F,Van Damme P, et al.
J Viral Hepat 2014,21 Suppl 1:5-33. doi:10.1111/jvh.12247
Askling HH, Rombo L, van Vollenhoven R, Hallen I, Thorner A, Nordin M, et al.
Travel Med Infect Dis 2014,12:134-142. doi: 10.1016/j.tmaid.2014.01.005
Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al.
Annals of internal medicine 2014 Mar 4;160(5):293-300. DOI: 10.7326/M13-1133
Smith BD, Beckett GA, Yartel A, Holtzman D, Patel N, Ward JW, McQuillan GM, et al.
American journal of public health 2014 Mar;104(3):474-81. DOI: 10.2105/AJPH.2013.301549
Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, … Roudot-Thoraval F, et al.
J Hepatol 2014. Mar 17. doi: 10.1016/j.jhep.2014.03.011
Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K.
Vaccine 2014,32:1507-1513. doi: 10.1016/j.vaccine.2013.10.088
Marinho RT, Vitor S, Velosa J.
J Gastrointestin Liver Dis 2014,23:85-90.
Lin J, Norder H, Uhlhorn H, Belak S, Widen F.
J Gen Virol 2014,95:557-570. doi: 10.1099/vir.0.059238-0
Shouval D.
J Hepatol 2014,60:1108-1109. doi: 10.1016/j.jhep.2014.03.004
Locarnini S, Shouval D.
J Virol 2014,88:6532. doi: 10.1128/JVI.00234-14
Innes H, Goldberg D, Dusheiko G, Hayes P, Mills PR, Dillon JF, et al.
J Hepatol 2014,60:1118-1126. doi:10.1016/j.jhep.2014.01.020
Baldo V, Bonanni P, Castro M, Gabutti G, Franco E, Marchetti F, et al.
Hum Vaccin Immunother 2014,10:129-137. doi: 10.4161/hv.26269
Romano L, Carsetti R, Tozzi AE, Mele A, Zanetti AR.
Hepatology 2014,59:349. doi: 10.1002/hep.26458
Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, et al.
Viral Hepat 2014,21:25-32. doi: 10.1111/jvh.12117
McDonald SA, Hutchinson SJ, Schnier C, McLeod A, Goldberg DJ.
Epidemiol Infect 2014,142:200-207. doi: 10.1017/S0950268813000617
Spada E, Romano L, Tosti ME, Zuccaro O, Paladini S, Chironna M,… Zanetti A,et al.
Clin Microbiol Infect 2014: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2014 Feb 16. doi: 10.1111/1469-0691.12591
Cohen MJ, Levy I, Barak O, Bloom AI, Fernandez-Ruiz M, Di Maio M,… Shouval D, et al.
Liver Int 2014: official journal of the International Association for the Study of the Liver. 2014 Feb 10. doi: 10.1111/liv.12486
Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, Van Damme P
Epidemiol Infect 2014,142:251-261. doi: 10.1017/S0950268813001064
Shouval D
J Hepatol 2014,60:239-240. doi:10.1016/j.jhep.2013.11.002
Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al.
Int J Epidemiol 2014,43:235-248. doi:10.1093/ije/dyt243
Zehender G, Ebranati E, Lai A, Luzzago C, Paladini S, Tagliacarne C, … Zanetti A, et al.
Infect Genet Evol 2014,25C:138-143. doi:10.1016/j.meegid.2014.04.016
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al.
N Engl J Med 2014,370:1604-1614 doi: 10.1056/NEJMoa1401561
Shouval D.
J Hepatol 2014,60:685-686.
Jilg W, Norder H, Kane M, Van Damme P, Vorsters A,
J Virol 2014,88:4605-4606.doi: 10.1128/JVI.03654-13
Hepatitis A.
Shouval D.
In: Viral Infections in Humans: Epidemiology and Control Edited by Kaslow D, LeDuc JW, Stanberry L. 5 ed: Springer Press; 2014. pp. in Press.

 

2013 – Reference list of hepatitis publications of the VHPB board members

Zehender G, Sorrentino C, Lai A, Ebranati E, Gabanelli E, Lo Presti A, Vujoševic D, Lauševic D, Terzić D, Shkjezi R, Bino S, Vratnica Z, Mugosa B, Galli M, Ciccozzi M.
Infect Genet Evol. 2013,17:223-30. doi: 10.1016/j.meegid.2013.04.003.
Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W
J Infect Dis 2013,207:497-500. doi:10.1093/infdis/jis688
Ward, J W
Topics in antiviral medicine 2013 Feb-Mar;21(1):15-9 ISSN:2161-5853
Ward, J. W.
Scand J Infect Dis 2013,45:796-799. doi:10.1016/j.cld.2012.09.011
Waldenstrom J, Konar J, Ekermo B, Norder H, Lagging M.
Scand J Infect Dis 2013,45:796-799. doi:10.3109/00365548.2013.797601
Hepatitis Vaccines.
Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A.
In: Vaccines. Edited by Plotkin SA, WA Orenstein PA. 6 ed; 2013. pp. 205-234.
Chronic hepatitis & other liver diseases.
Van Damme P, Van Herck K, Michielsen PS, Francque S, Shouval D.
In: Oxford Textbook of Public Health. Edited by Detels R, Beaglehole R, Lansang MA, Gulliford M. 6 ed: Oxford University Press; 2013. pp. in press.
Van Damme P, Leuridan E, Hendrickx G, Vorsters A, Theeten H, Leino T, et al.
Bmj 2013;347:f4057. doi:10.1136/bmj.f4057
Teoharov P, Kevorkyan A, Petrova N, Baltadzhiev I, Van Damme P.
Pediatr Infect Dis J 2013,32:51-53. doi: 10.1097/INF.0b013e31826f354e
Smith BD, Holtzman D, Ward JW..
Annals of internal medicine 2013 May 7;158(9):705. doi: 10.7326/0003-4819-158-9-201305070-00016
Shouval D, Shibolet O.
Semin Liver Dis 2013,33:167-177. doi: 10.1055/s-0033-1345722
Shouval D
J Hepatol 2013,58:203-204. doi: 10.1016/j.jhep.2012.11.008
Shouval D
J Hepatol 2013,58:641-642. doi:10.1016/j.jhep.2013.01.008
Shouval D
J Hepatol 2013,58:1063-1064. doi: 10.1016/j.jhep.2013.03.002
Shouval D
J Hepatol 2013,59:201-202. doi: 10.1016/j.jhep.2013.05.013
Shouval D
J Hepatol 2013,59:643-645. doi: 10.1016/j.jhep.2013.09.005
Shouval D
J Hepatol 2013,59:1151-1152. doi: 10.1016/j.jhep.2013.07.007
Shepherd SJ, Kean J, Hutchinson SJ, Cameron SO, Goldberg DJ, Carman WF, et al.
J Clin Virol 2013,57:29-35. doi: 10.1016/j.jcv.2013.01.002
Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries RV.
Pediatr Infect Dis J 2013,32:307-313. doi: 10.1097/INF.0b013e31827bd1b0
Schnier C, Wallace L, Tempelton K, Aitken C, Gunson RN, Molyneaux P, … Goldberg DJ, et al.
Epidemiol Infect 2013:1-10. doi: 10.1017/S0950268813003105
Samimi-Rad K, Asgari F, Nasiritoosi M, Esteghamati A, Azarkeyvan A, Eslami SM,… Norder H, et al.
Hepat Mon 2013,13:e7699.doi: 10.5812/hepatmon.7699
Romano L, Velati C, Cambie G, Fomiatti L, Galli C, Zanetti AR, et al.
Blood Transfus 2013,11:281-288. doi: 10.2450/2012.0160-12
Hepatitis B vaccination: an update on a strategy of success.
Romano L, Paladini S, Zanetti AR.
In: Chronic viral hepatitis B and C. Edited by Floreani A: Edizioni Minerva Medica; 2013. pp. 33-37.
Romano L, Paladini S, Zanetti AR.
Ann Ig 2013,25:169-180. doi:10.7416/ai.2013.1919
Ribeiro RT, Marinho RT, Sanches JM.
IEEE Trans Biomed Eng 2013,60:1336-1344. doi:10.1109/TBME.2012.2235438
Ramezani F, Norouzi M, Sarizade GR, Poortahmasebi V, Kalantar E, Magnius L, … Norder H,et al.
Iran J Allergy Asthma Immunol 2013,12:269-275.
Palmateer NE, Hutchinson SJ, Innes H, Schnier C, Wu O, Goldberg DJ, et al.
Int J Drug Policy 2013,24:85-100. doi:10.1016/j.drugpo.2012.08.006
Estimate of hepatitis B incidence in Catalonia and its relationship with immigration rates and vaccination coverage using generalized additive models.
Oviedo M, Muñoz P, Domínguez A.
Vacunas 2013,14:103-110.
Ott JJ, Wiersma ST.
Int J Infect Dis 2013,17:e939-944. doi:10.1016/j.ijid.2013.04.012
O’Leary MC, Sarwar M, Hutchinson SJ, Weir A, Schofield J, McLeod A, … Goldberg DJ, et al.
Travel Med Infect Dis 2013,11:301-30doi: 10.1016/j.tmaid.2013.08.001
Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Lu M, … Ward, J.W. and Chronic Hepatitis Cohort Study, Investigators
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013 Jan;56(1):40-50. doi:10.1093/cid/cis815
Ngo-Metzger Q, Ward JW, Valdiserri RO., et al.
Annals of internal medicine 2013 Sep 3;159(5):364-5. doi: 10.1016/j.tmaid.2013.08.001
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST
Hepatology 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141
Mihigo R, Nshimirimana D, Hall A, Kew M, Wiersma S, Clements CJ.
Vaccine 2013,31:341-346. doi:10.3748/wjg.v19.i40.6703
McDonald SA, Hutchinson SJ, Palmateer NE, Allen E, Cameron SO, Goldberg DJ, et al.
J Hepatol 2013,58:460-466. doi: 10.1016/j.jhep.2012.11.004
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, … Goldberg DJ,et al.
Hepatology 2013,58:1598-1609.doi: 10.1002/hep.26431
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P.
Clin Infect Dis 2013,57 Suppl 2:S39-45. doi: 10.1093/cid/cit296
Marinho RT, Barreira DP.
World J Gastroenterol 2013,19:6703-6709. doi:10.3748/wjg.v19.i40.6703
Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A,…Goldberg DJ, et al.
Hepatology 2013,57:451-460. doi:10.1002/hep.26051
Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H,Ward JW, et al.
Hepatology 2013 Sep;58(3):856-62. doi:10.1002/hep.26286
Hatzakis A,  Van Damme P,…,Dominguez AGoldberg D, Roudot-Thoraval F,Shouval D et al.
J Viral Hepat 2013,20 Suppl 2:1-20. doi:10.1111/jvh.12120.
Fretz R, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, et al.
Swiss Med Wkly 2013,143:w13793. doi:10.4414/smw.2013.13793.
FitzSimons D, McMahon B, Hendrickx G, Vorsters A, Van Damme P.
Int J Circumpolar Health 2013,72. doi: 10.3402/ijch.v72i0.21163.
FitzSimons D, Hendrickx G, Vorsters A, Van Damme P..
Vaccine 2013,31:584-590. doi:10.1016/j.vaccine.2012.10.101.
Ferreira AO, Marinho RT, Velosa J, Costa JB.
BMJ Case Rep 2013,2013. doi: 10.1136/bcr-2013-008774.
Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho RT.
Ann Oncol 2013,24 Suppl 2:ii24-29. ;doi: 10.1093/annonc/mdt054.
Cui F, Drobeniuc J, Hadler SC, Hutin YJ, Ma F, Wiersma S, et al.
Vaccine 2013,31 Suppl 9:J79-84 doi: 10.1016/j.vaccine.2013.05.054
Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D, et al.
World J Gastroenterol 2013,19:2521-2528. doi: 10.3748/wjg.v19.i16.2521
Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D,…..Bonanni, P. et al.
Hum Vaccin Immunother 2013,9:1119-1128. doi: 10.4161/hv.23827
Boccalini S, Pellegrino E, Tiscione E, Pesavento G, Bechini A, Levi M,…,Bonanni, P. et al.
Hum Vaccin Immunother 2013,9..
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F.
J Hepatol 2013,58:593-608. doi: 10.1016/j.jhep.2012.12.005
Binhas M, Amathieu R, Campillo B, Roudot-Thoraval F, Azoulay D, Plaud B, et al.
Ann Fr Anesth Reanim 2013,32:302-306. doi: 10.1016/j.annfar.2013.02.017
Baylis, S. A., Jilg, W. et al. and Group, H. E. V. Collaborative Study.
Emerg Infect Dis 2013,19:729-735. doi: 10.3201/eid1905.121845
Barrault C, Roudot-Thoraval F, Tran Van Nhieu J, Atanasiu C, Kluger MD, Medkour F, et al.
Clin Res Hepatol Gastroenterol 2013,37:347-352. doi: 10.1016/j.clinre.2012.11.003
Averhoff F, Kolwaite A, Ward JW., et al.
Vaccine 2013 Dec 27;31 Suppl 9:J5-7..doi: 10.1016/j.vaccine.2013.04.022
Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, … Goldberg DJ, et al.
Clin Infect Dis 2013,57 Suppl 2:S80-89.doi: 10.1093/cid/cit306
Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al.
Journal of viral hepatitis 2013 Nov;20(11):745-60.doi: 10.1111/jvh.12173
Wiersma S. et al.
Vaccine 2013 31(2): 285-286. doi: 10.1016/j.vaccine.2012.10.102